PUBLIC RESEARCH DOSSIER
ALVO · NasdaqAlvotech
Manufacturing · Biological Products, (No Diagnostic Substances)完成交易日收盘US$4.54+1.34%行情日期 2026-11-03 · 非实时
公开资料页汇总Alvotech（ALVO）的已发布行情、估值、风险、财务摘要与同业对比。行情截至2026-11-03，非实时；缺失值不按零处理。
股价走势
复权收盘价（美元）
2025-10-31 — 2026-11-03253 个交易日样本
ALVOUS$4.54
查看图表数据
| 日期 | ALVO |
|---|---|
| 2025-10-31 | 7.65 |
| 2025-11-03 | 5.03 |
| 2025-11-04 | 4.83 |
| 2025-11-05 | 4.88 |
| 2025-11-06 | 5.06 |
| 2025-11-07 | 5.71 |
| 2025-11-10 | 5.48 |
| 2025-11-11 | 5.58 |
| 2025-11-12 | 5.6 |
| 2025-11-13 | 5.52 |
| 2025-11-14 | 5.49 |
| 2025-11-17 | 5.14 |
| 2025-11-18 | 5.11 |
| 2025-11-19 | 5.23 |
| 2025-11-20 | 5.06 |
| 2025-11-21 | 5.14 |
| 2025-11-24 | 5.47 |
| 2025-11-25 | 5.34 |
| 2025-11-26 | 5.15 |
| 2025-11-28 | 5.1 |
| 2025-12-01 | 4.84 |
| 2025-12-02 | 4.6 |
| 2025-12-03 | 4.64 |
| 2025-12-04 | 5.07 |
| 2025-12-05 | 5.47 |
| 2025-12-08 | 5.45 |
| 2025-12-09 | 5.56 |
| 2025-12-10 | 5.53 |
| 2025-12-11 | 5.75 |
| 2025-12-12 | 5.57 |
| 2025-12-15 | 5.4 |
| 2025-12-16 | 5.04 |
| 2025-12-17 | 5 |
| 2025-12-18 | 4.73 |
| 2025-12-19 | 4.9 |
| 2025-12-22 | 4.94 |
| 2025-12-23 | 4.81 |
| 2025-12-24 | 5.29 |
| 2025-12-26 | 5.26 |
| 2025-12-29 | 4.97 |
| 2025-12-30 | 5.05 |
| 2025-12-31 | 5.13 |
| 2026-01-02 | 5 |
| 2026-01-05 | 4.9 |
| 2026-01-06 | 4.58 |
| 2026-01-07 | 4.66 |
| 2026-01-08 | 4.73 |
| 2026-01-09 | 4.64 |
| 2026-01-12 | 4.93 |
| 2026-01-13 | 4.83 |
| 2026-01-14 | 5 |
| 2026-01-15 | 4.95 |
| 2026-01-16 | 4.92 |
| 2026-01-20 | 4.96 |
| 2026-01-21 | 5.04 |
| 2026-01-22 | 5.17 |
| 2026-01-23 | 5.26 |
| 2026-01-26 | 5.33 |
| 2026-01-27 | 5.31 |
| 2026-01-28 | 5.29 |
| 2026-01-29 | 5.42 |
| 2026-01-30 | 5.37 |
| 2026-02-02 | 5.32 |
| 2026-02-03 | 5.21 |
| 2026-02-04 | 5.09 |
| 2026-02-05 | 4.99 |
| 2026-02-06 | 5.12 |
| 2026-02-09 | 5.14 |
| 2026-02-10 | 5.2 |
| 2026-02-11 | 4.85 |
| 2026-02-12 | 4.71 |
| 2026-02-13 | 4.64 |
| 2026-02-17 | 4.64 |
| 2026-02-18 | 4.37 |
| 2026-02-19 | 4.32 |
| 2026-02-20 | 4.14 |
| 2026-02-23 | 4.22 |
| 2026-02-24 | 4.11 |
| 2026-02-25 | 4.09 |
| 2026-02-26 | 4.16 |
| 2026-02-27 | 3.99 |
| 2026-03-02 | 3.96 |
| 2026-03-03 | 3.8 |
| 2026-03-04 | 3.89 |
| 2026-03-05 | 4.16 |
| 2026-03-06 | 4.01 |
| 2026-03-09 | 4.02 |
| 2026-03-10 | 3.88 |
| 2026-03-11 | 3.73 |
| 2026-03-12 | 3.54 |
| 2026-03-13 | 3.47 |
| 2026-03-16 | 3.61 |
| 2026-03-17 | 3.82 |
| 2026-03-18 | 3.8 |
| 2026-03-19 | 3.58 |
| 2026-03-20 | 3.53 |
| 2026-03-23 | 3.33 |
| 2026-03-24 | 3.13 |
| 2026-03-25 | 3.14 |
| 2026-03-26 | 3.24 |
| 2026-03-27 | 3.11 |
| 2026-03-30 | 3.29 |
| 2026-03-31 | 3.43 |
| 2026-04-01 | 3.62 |
| 2026-04-02 | 3.65 |
| 2026-04-06 | 3.79 |
| 2026-04-07 | 3.39 |
| 2026-04-08 | 3.58 |
| 2026-04-09 | 3.6 |
| 2026-04-10 | 3.62 |
| 2026-04-13 | 3.71 |
| 2026-04-14 | 3.53 |
| 2026-04-15 | 3.66 |
| 2026-04-16 | 3.62 |
| 2026-04-17 | 3.61 |
| 2026-04-20 | 3.62 |
| 2026-04-21 | 3.51 |
| 2026-04-22 | 3.5 |
| 2026-04-23 | 3.38 |
| 2026-04-24 | 3.38 |
| 2026-04-27 | 3.3 |
| 2026-04-28 | 3.52 |
| 2026-04-29 | 3.3 |
| 2026-04-30 | 3.34 |
| 2026-05-01 | 3.46 |
| 2026-05-04 | 3.52 |
| 2026-05-05 | 3.5 |
| 2026-05-06 | 3.57 |
| 2026-05-07 | 3.2 |
| 2026-05-08 | 3.26 |
| 2026-05-11 | 3.59 |
| 2026-05-12 | 3.55 |
| 2026-05-13 | 3.67 |
| 2026-05-14 | 3.43 |
| 2026-05-15 | 3.31 |
| 2026-05-18 | 3.25 |
| 2026-05-19 | 3.28 |
| 2026-05-20 | 3.3 |
| 2026-05-21 | 3.38 |
| 2026-05-22 | 3.34 |
| 2026-05-26 | 3.42 |
| 2026-05-27 | 3.44 |
| 2026-05-28 | 3.43 |
| 2026-05-29 | 3.36 |
| 2026-06-01 | 3.22 |
| 2026-06-02 | 3 |
| 2026-06-03 | 3.14 |
| 2026-06-04 | 3.74 |
| 2026-06-05 | 3.54 |
| 2026-06-08 | 4.24 |
| 2026-06-09 | 4.16 |
| 2026-06-10 | 4.14 |
| 2026-06-11 | 4.22 |
| 2026-06-12 | 4.17 |
| 2026-06-15 | 4.24 |
| 2026-06-16 | 3.87 |
| 2026-06-17 | 3.92 |
| 2026-06-18 | 3.92 |
| 2026-06-22 | 3.65 |
| 2026-06-23 | 3.7 |
| 2026-06-24 | 3.7 |
| 2026-06-25 | 3.48 |
| 2026-06-26 | 3.68 |
| 2026-06-29 | 3.72 |
| 2026-06-30 | 3.69 |
| 2026-07-01 | 3.58 |
| 2026-07-02 | 3.61 |
| 2026-07-06 | 3.46 |
| 2026-07-07 | 3.49 |
| 2026-07-08 | 3.4 |
| 2026-07-09 | 3.32 |
| 2026-07-10 | 3.28 |
| 2026-07-13 | 3.38 |
| 2026-07-14 | 3.3 |
| 2026-07-15 | 3.38 |
| 2026-07-16 | 3.37 |
| 2026-07-17 | 3.46 |
| 2026-07-20 | 3.41 |
| 2026-07-21 | 3.52 |
| 2026-07-22 | 3.19 |
| 2026-07-23 | 3.18 |
| 2026-07-24 | 3.06 |
| 2026-07-27 | 3.08 |
| 2026-07-28 | 3.1 |
| 2026-07-29 | 3.53 |
| 2026-07-30 | 3.57 |
| 2026-07-31 | 4.12 |
| 2026-08-03 | 3.79 |
| 2026-08-04 | 3.84 |
| 2026-08-05 | 3.76 |
| 2026-08-06 | 3.8 |
| 2026-08-07 | 3.81 |
| 2026-08-10 | 3.77 |
| 2026-08-11 | 3.8 |
| 2026-08-12 | 4.01 |
| 2026-08-13 | 4.09 |
| 2026-08-14 | 4.06 |
| 2026-08-17 | 3.88 |
| 2026-08-18 | 3.95 |
| 2026-08-19 | 3.99 |
| 2026-08-20 | 4.27 |
| 2026-08-21 | 4.43 |
| 2026-08-24 | 5.25 |
| 2026-08-25 | 5.05 |
| 2026-08-26 | 4.91 |
| 2026-08-27 | 4.88 |
| 2026-08-28 | 4.95 |
| 2026-08-31 | 5.19 |
| 2026-09-01 | 5.24 |
| 2026-09-02 | 5.34 |
| 2026-09-03 | 5.38 |
| 2026-09-04 | 5.32 |
| 2026-09-08 | 5.19 |
| 2026-09-09 | 5.21 |
| 2026-09-10 | 5.24 |
| 2026-09-11 | 5.29 |
| 2026-09-14 | 5.05 |
| 2026-09-15 | 5.02 |
| 2026-09-16 | 5.1 |
| 2026-09-17 | 5.34 |
| 2026-09-18 | 5.87 |
| 2026-09-21 | 5.88 |
| 2026-09-22 | 5.84 |
| 2026-09-23 | 5.81 |
| 2026-09-24 | 5.88 |
| 2026-09-25 | 5.75 |
| 2026-09-28 | 6.15 |
| 2026-09-29 | 5.92 |
| 2026-09-30 | 5.8 |
| 2026-10-01 | 5.62 |
| 2026-10-02 | 5.45 |
| 2026-10-05 | 6.11 |
| 2026-10-06 | 6.14 |
| 2026-10-07 | 5.85 |
| 2026-10-08 | 5.67 |
| 2026-10-09 | 5.78 |
| 2026-10-12 | 5.5 |
| 2026-10-13 | 5.38 |
| 2026-10-14 | 5.17 |
| 2026-10-15 | 5.31 |
| 2026-10-16 | 5 |
| 2026-10-19 | 5.03 |
| 2026-10-20 | 5.12 |
| 2026-10-21 | 5.13 |
| 2026-10-22 | 4.79 |
| 2026-10-23 | 4.58 |
| 2026-10-26 | 4.62 |
| 2026-10-27 | 4.75 |
| 2026-10-28 | 4.94 |
| 2026-10-29 | 4.89 |
| 2026-10-30 | 4.65 |
| 2026-11-02 | 4.48 |
| 2026-11-03 | 4.54 |
1、3、6、12个月分别按21、63、126、252个交易日取区间；缺失日期不从区间外补齐。
使用已有每日复权收盘样本，非实时行情；图中价格可能与未复权收盘报价不同。
01 · MARKET FRAME
行情、估值与风险
基于已完成交易日和已发布财务资料
区间涨跌幅
区间涨跌幅使用复权收盘价；估值和风险指标缺失时显示为—，不按零处理。
02 · FINANCIAL TRACE
财务摘要
公开页仅显示最近3个已校验报告期
年度财务走势
百万美元 · 年度报告期
所选指标暂无已校验的年度资料，缺失值不按零处理。
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| 营收 | — | — | — |
| 净利润 | — | — | — |
| 自由现金流 | — | — | — |
| 股份数 | 312 | 301.8 | 266.8 |
| 债务 | — | — | — |
| 总资产 | — | — | — |
金额及股份数均以百万为单位。缺失或待核验数据不按零处理。
03 · PEER SET
同业对比
同一细分行业中市值最接近的公司
| 公司 | 市值 | 近250日涨跌幅 | 市盈率 | 距52周高点 | 波动率 |
|---|---|---|---|---|---|
| MAZEMaze治疗 | US$1.8B | -0.5% | — | -37.8% | +67.4% |
| VIR维尔生物技术 | US$1.9B | +113.7% | — | -6% | +64.1% |
| REPL瑞普利缪恩 | US$2B | +130.2% | — | +6% | +187.1% |
| NVAX诺瓦瓦克斯医药 | US$1.6B | +28.9% | — | -24.5% | +70.9% |
同业由已覆盖公司的行业分类和市值接近度确定，仅用于横向研究；缺失数据不按零处理。